Innova Captab Convenes 22nd AGM, Reports 31.1% Revenue Growth in FY2025-26
Innova Captab Limited has filed its 22nd AGM notice for June 29, 2026, along with its Integrated Annual Report for FY2025-26. The company reported consolidated revenue of ₹1,630.02 crore (+31.1% YoY), EBITDA of ₹250.34 crore (+26.3%), and PAT of ₹140.92 crore (+9.9%). CDMO revenue grew 23.8% to ₹1,133.35 crore while Branded Generics surged 51.4% to ₹496.67 crore. The AGM agenda includes re-appointments of key directors and auditors.

*this image is generated using AI for illustrative purposes only.
Innova Captab Limited has convened its 22nd Annual General Meeting on Monday, June 29, 2026, at 11:00 AM IST, to be held through Video Conferencing and Other Audio-Visual Means in accordance with circulars issued by the Ministry of Corporate Affairs and SEBI. The company has simultaneously submitted its Integrated Annual Report for the financial year ended March 31, 2026, pursuant to Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The annual report, comprising standalone and consolidated financial statements, Directors' Report, Independent Auditors' Report, and other statutory documents, has been dispatched via email to shareholders with registered email addresses. The Integrated Annual Report is also available on the company's website.
Key AGM Details
The following table summarises the important dates and timelines for the 22nd AGM:
| Event: | Date | Time |
|---|---|---|
| AGM Date: | June 29, 2026 | 11:00 AM IST |
| Record Date (Cut-off): | June 22, 2026 | — |
| E-Voting Start: | June 26, 2026 | 09:00 AM IST |
| E-Voting End: | June 28, 2026 | 05:00 PM IST |
The AGM agenda includes adoption of audited standalone and consolidated financial statements for FY2025-26, re-appointment of Mr. Jayant Vasudeo Rao as Whole-Time Director who retires by rotation, and re-appointment of M/s. B S R & Co. LLP as Statutory Auditors for a second term of five consecutive years from FY2026-27 to FY2030-31. Special business includes ratification of remuneration of ₹80,000 payable to M/s. Gurvinder Chopra & Co. as Cost Auditors for FY2027, and re-appointments of Mr. Manoj Kumar Lohariwala as Whole-Time Director and Mr. Vinay Lohariwala as Managing Director, each for a fresh term of five years from March 18, 2027 to March 17, 2032, at an annual remuneration of ₹25,000,000 each. The AGM also seeks approval for re-appointment of four Non-Executive Independent Directors — Mr. Sudhir Kumar Bassi, Ms. Priyanka Dixit, Mr. Mahendar Korthiwada, and Mr. Shirish Gundopant Belapure — each for a second term of five consecutive years from April 1, 2027 to March 31, 2032.
FY2025-26 Financial Performance
Innova Captab delivered strong consolidated financial results for FY2025-26. The following table presents key consolidated financial metrics:
| Metric: | FY2025-26 | FY2024-25 | Change (%) |
|---|---|---|---|
| Revenue from Operations: | ₹1,630.02 crore | ₹1,243.68 crore | +31.1% |
| EBITDA: | ₹250.34 crore | ₹198.20 crore | +26.3% |
| EBITDA Margin: | ~15.4% | ~15.9% | — |
| Profit After Tax (PAT): | ₹140.92 crore | ₹128.26 crore | +9.9% |
On a standalone basis, revenue from operations increased 35.6% to ₹12,988.14 million in FY2026 from ₹9,580.61 million in FY2025. Standalone EBITDA increased to ₹1,646.10 million from ₹1,390.74 million, a growth of 18.4%. Standalone profit for FY2026 stood at ₹836.92 million, a decline of 6.46% from ₹894.70 million in FY2025, primarily impacted by fixed costs of the Kathua, Jammu facility. The company's market capitalisation as on March 31, 2026 stood at ₹3,948 crore. An interim dividend of ₹2 per share was declared and paid during the year.
Business Segment Performance
The company restructured its operations into two consolidated business areas — CDMO Services & Products and Branded Generics. The following table highlights segment-wise revenue performance:
| Segment: | FY2025-26 | FY2024-25 | YoY Growth |
|---|---|---|---|
| CDMO Revenue: | ₹1,133.35 crore | ₹915.62 crore | +23.8% |
| Branded Generics Revenue: | ₹496.67 crore | ₹328.06 crore | +51.4% |
The CDMO business contributed approximately 70% to total revenue, serving over 350 clients across 60+ countries with a portfolio of 4,200+ products. The Branded Generics business is supported by a domestic distribution network of over 2,50,000 touchpoints. Export contribution stood at 31.3% of total revenue in FY2026. Key return ratios for FY2026 included ROCE of 14.5% and ROE of 12.9%.
Operational and Strategic Highlights
The company's greenfield facility at Kathua, Jammu commenced operations effective January 14, 2025 and operated for the full year in FY2026. The facility received WHO-GMP, Good Laboratory Practices, and GMP certificates from the State Drugs Controller, Jammu & Kashmir, as well as PIC/S (SMDC, Ukraine) certification. The Baddi facility received GMP compliance certification from the UK-MHRA. R&D investment for FY2026 stood at ₹7.00 crore, up from ₹6.55 crore in FY2025 and ₹5.70 crore in FY2024, supported by a team of 60+ scientists and engineers. The company's revenue from operations has grown from ₹800.53 crore in FY2022 to ₹1,630.02 crore in FY2026, reflecting a CAGR of ~19.4%, while EBITDA grew at a CAGR of ~26.1% and PAT at ~21.8% over the same period. As on March 31, 2026, the company employed 2,298 permanent employees on a standalone basis and 3,387 on a group level.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0DUT01020/a06cb9d363c54e6c.pdf
Historical Stock Returns for Innova Captab
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.81% | +3.11% | +16.02% | +21.69% | -2.30% | +61.17% |
How soon could the Kathua, Jammu facility reach full operational capacity, and what revenue contribution is expected once fixed cost absorption improves to restore standalone PAT growth?
With Branded Generics growing at 51.4% YoY, does Innova Captab plan to expand its domestic distribution network beyond 2,50,000 touchpoints or launch new therapeutic segments to sustain this momentum?
Given that R&D spending remains relatively modest at ₹7 crore, will the company significantly scale up its research investments to strengthen its CDMO pipeline and compete for higher-value complex formulation contracts?


































